[ad_1]
reThe European Medicines Agency EMA wants to decide on the approval of another crown vaccine on January 6. It is about the preparation of the American manufacturer Moderna, as announced by the authority on Thursday night in Amsterdam. That’s eight days earlier than originally planned.
The Moderna vaccine could therefore be the second most likely to hit the EU market. The EMA wants to decide on the approval of the vaccine by the manufacturers Pfizer and Biontech as of next Monday. As soon as the EU Commission gives the green light, vaccinations could take place in the EU in December. The approval of the Commission is a matter of form.
Also admission to the United States before graduation.
The EMA had previously stated that it would decide on the Moderna vaccine on January 12. The drug company sent the latest data packet on Thursday, earlier than expected. “This contains information specific to production for the EU market,” the authority said. In the scientific evaluation of all the data and studies, however, no compromises are made in terms of safety and efficacy.
Meanwhile, an advisory group to the US FDA discussed the request for emergency approval for the Moderna vaccine on Thursday. Scientists, doctors and employees of authorities and pharmaceutical companies discussed various aspects of the preparation, its effectiveness and side effects for different population groups through a video link.
At the end of the full-day session, a recommendation to the FDA was expected on whether the vaccine should receive emergency approval in the United States. The final decision is left to the FDA and was expected shortly after the meeting ended. US government officials had already announced that vaccines could begin early next week after an emergency approval.
